HPV Infection Clinical Trial
Official title:
Randomised, Double-blind, Placebo-controlled Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV-16 Infected Women With Normal Cytology, CIN1 or CIN2
BS-01 is a randomised, double-blind, placebo-controlled, phase 1 dose escalation study assessing safety, tolerability and immunogenicity of FluBHPVE6E7, changes in the HPV infection status and cervical cytology, and biodistribution in HPV-16 infected women with normal cytology, CIN1 or CIN2. The safety and immunogenicity of two dose levels, 7.5 log10 and 9.0 log10 fTCID50/dose of FluBHPVE6E7 are assessed after three subcutaneous administrations. In addition the safety of 9.0 log10 fTCID50/dose of FluBHPVE6E7 is assessed after three intradermal or intramuscular administrations.
BS-01 is a randomised, placebo-controlled, double- blind phase 1 dose-escalation study in women with normal cytology, CIN1 or CIN2. The primary objective is to assess the safety and tolerability of FluBHPVE6E7. Secondary objectives are the assessment of the systemic immune responses to immunisations with FluBHPVE6E7, changes in HPV infection status and cervical cytology, and biodistribution. Study medication is administered three times (Day 0, Week 4, Week 12). Study participants are randomised at a ratio of 3:1 for FluBHPVE6E7 or placebo. The first cohort is treated subcutaneously at dose level 7.5 log10 fTCID50/dose. The second cohort is treated subcutaneously at 9.0 log10 fTCID50/dose. Interim safety reviews are performed by a Data Monitoring Committee. After completion of the dose-escalation and in order to collect additional safety data on the highest safe and tolerated dose level, additional study participants are enrolled into expansion cohorts treated three times subcutaneously, intradermally or intramuscularly at 9.0 log10 fTCID50/dose. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04098744 -
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
|
Phase 2 | |
| Completed |
NCT04083196 -
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
|
Phase 1 | |
| Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
| Withdrawn |
NCT04430907 -
HPV Vaccine in Postpartum Women
|
||
| Recruiting |
NCT02593968 -
Yallaferon in Chinese Population
|
Phase 2 | |
| Completed |
NCT04711265 -
Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
|
||
| Completed |
NCT02263378 -
A New Supplement for the Immune Response to HPV Infection
|
N/A | |
| Completed |
NCT05234112 -
Prevention and Screening Towards Elimination of Cervical Cancer
|
N/A | |
| Completed |
NCT04590521 -
HPV Vaccine Immunity in High-risk Women
|
Phase 4 | |
| Recruiting |
NCT05829629 -
Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women
|
Phase 1 | |
| Recruiting |
NCT06052033 -
Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection
|
N/A | |
| Recruiting |
NCT05051852 -
HPV Viral Load in Predicting the Prognosis of LSIL
|
||
| Completed |
NCT04155294 -
Re-Evaluation of Annual Cytology Using HPV Testing to Upgrade Prevention in Women Living With HIV
|
||
| Active, not recruiting |
NCT06452004 -
Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC)
|
N/A | |
| Completed |
NCT06177236 -
Clinic or Self-Sampling for Cervical Cancer Screening
|
N/A | |
| Active, not recruiting |
NCT04794660 -
The Study for the "Cervical Cancer Screening and Treatment Algorithms Study Using HPV Testing in Africa"
|
Phase 3 | |
| Recruiting |
NCT05509413 -
DEFLAGYN® Vaginal Gel and Spontaneous Remission and Regression of Unclear Cervical Smears and HPV High-risk Infections
|
N/A | |
| Recruiting |
NCT06137950 -
Interferon Alpha Therapy for Cervical CINI and HPV Infection
|
Phase 1 | |
| Recruiting |
NCT04171505 -
Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN.
|
||
| Active, not recruiting |
NCT05524025 -
The SPOT-HPV Study
|